Genomic Testing Programs in Urology Empowering Patient Care
Chicago Marriott Magnificent Mile Hotel, Chicago, IL
Booth 410

PROSTATENOW is a hereditary germline test for people who have been diagnosed with prostate cancer or have a family history of prostate cancer or other hereditary cancer disorders.

PROSTATENOW provides valuable insights in determining

a patient’s risk and potential treatment plans

  • Assess risk of developing prostate cancer
    Family history, rare pathogenic mutations (RPMs) and genetic risk score (GRS) are three measures of inherited risk, allowing for a comprehensive analysis of risk of developing prostate cancer. Men with an increased risk of prostate cancer may consider earlier and more frequent prostate cancer screening and may evaluate their chances of passing on this risk to their offspring.
  • Assess prognosis for localized prostate cancer
    ProstateNow supplements traditional clinical variables like Gleason score and PSA levels in determining risk for disease progression and can inform decisions on prostate cancer treatment, such as pursuing active surveillance versus definitive treatment with surgery or radiation.
  • Predict therapeutic responses for advanced prostate cancer
    ProstateNow screens for pathogenic mutations in DNA repair genes and identifies patients who may respond better to targeted treatments, such as PARP inhibitors and platinum-based chemotherapies.
  • Effortless Implementation
    Integrate genetic testing smoothly into your existing workflow without disruption.
  • Streamlined Processes
    Benefit from an efficient testing procedure that saves time and resources.
  • Collaborative Care
    Work alongside genetic counselors to translate test results into meaningful patient care strategies.
Leveraging data
to improve results
  • PROSTATENOW includes all known prostate cancer susceptibility genes
  • Includes >200 prostate cancer risk-associated SNPs for calculating GRS in multiple races
Introducing
PROSTATENOW 2.0
A next-generation sequencing (NGS) panel that analyzes 28 genes relevant to prostate cancer, designed to assess risk, predict prognosis, guide treatment decisions, and inform family members. This test integrates clinical guidelines, emerging science, and therapy choice in a single, powerful panel.

A comprehensive germline NGS panel analyzing genes recommended by NCCN guidelines and additional novel implicated genes, as well as risk-associated SNPs for prostate cancer. ProstateNow 2.0 now tests for the MMS22L & BlK genes, potential major genes associated with prostate cancer susceptibility.
HSD3B1
What is the importance
of the MMS22L gene?
PROSTATENOW & PROSTATENOW 2.0 are the only germline panels that include genotyping of HSD3B1 (1245C), an important biomarker for predicting response to androgen deprivation therapy (ADT). This common risk allele in HSD3B1 is associated with increased resistance to ADT, and patients carrying this variant tend to develop castration-resistant prostate cancer more rapidly.
Mutations in the MMS22L gene have been linked to a higher risk of prostate cancer, especially in men of Ashkenazi Jewish ancestry. Its carrier rate and impact are similar to those of BRCA2, one of the most well-known cancer-risk genes. This discovery sheds light on a new marker that could enhance early risk detection and inform more personalized treatment options.
Results
Provide information and guidance related to a patient’s inherited mutation analysis. Results will both aid guidance on inherited risk and determine eligibility for response to PARPi inhibitors.
  • RPM results include:
    • Pathogenic
    • Likely Pathogenic
    • Negative
    • Variants of Unknown Significance
  • ADT Implication (HSD3B1)
    • Present or not
    • Patient likelihood of response to ADT
  • GRS results include
    • Low
    • Intermediate
    • High
FDA-Cleared IVD Comprehensive
Genomic Profiling Panel
OncoTarget 500® is tissue-based, clinically, and analytically validated
for all solid malignant neoplasms.
Learn more
FDA Cleared CE-IVD Marked Comprehensive Kitted Solution with Bioinformatics
Streamlined Workflow, Fast and Reliable
Excellent Results By A Large Prospective Study with Leading Academic Center​
Excellent Sensitivity and Specificity
Cleared For All Solid Malignant Neoplasms
30+ Validation Studies
When Every Core Counts, Every Step Matters
In prostate biopsy workflows, even small pre-analytical errors - manual data entry, mislabeling, or tissue fragmentation - can undermine diagnostic accuracy. TWO-D by DigitCells was engineered to restore integrity to the entire process, ensuring data accuracy, specimen preservation, and end-to-end traceability.
Learn more
Discover how Genomic Programs can enhance your practice and improve patient outcomes.
© GoPath Global, Inc. 2025 All rights reserved
Booth 410
References:
1.Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63–89. doi:10.14740/wjon.1191 2.American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022. 3.Pilié PG, et al. Germline genetic variants in men with prostate cancer
and one or more additional cancers. Cancer. 2017;123(20):3925-3932. doi:10.1002/cncr.30817 4.Mucci LA, Hjelmborg JB, Harris JR, et al. Familial risk and heritability of cancer among twins in Nordic countries. JAMA. 2016;315(1):68-76. doi: 10.1001/jama.2015.17703 5.Bhanji W, Isaacs
WB, Xu J, et al. Prostate Cancer Predisposition. Urol Clin North Am. 2021;48(3):283-296. doi:10.1016/j.ucl.2021.03.001 6.Xu J, Labbate CV, Isaacs WB, Helfand BT. Inherited risk assessment of prostate cancer: it takes three to do it right. Prostate Cancer Prostatic Dis. 2020;23(1):59-61.
doi:10.1038/s41391-019-0165-y 7.Ewing CM, Ray AM, Lange EM, et al. Germline Mutations in HOXB13 and Prostate-Cancer Risk. N Engl J Med. 2012;366(2):141–149. doi: 10.1056/NEJMoa1110000 8.Leongamornlert D, Saunders E, Dadaev T, et al. Frequent germline deleterious mutations
in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br J Cancer. 2014;110(6),1663–1672. doi:10.1038/bjc.2014.30 9.Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J
Med. 2016;375(5):443-453. doi:10.1056/NEJMoa1603144 10. Shi Z, Lu L, Resurreccion WK, et al. Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis. Prostate. 2022;82(1):107-119. doi:10.1002/pros.24252
11.Xu J, Isaacs WB, Mamawala M, et al. Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients. Prostate. 2021;81(10):703-709. doi:10.1002/pros.24140 12.Hettel, D., Sharifi, N. HSD3B1 status as a biomarker of androgen
deprivation resistance and implications for prostate cancer. Nat Rev Urol . 2018;15(3):191-196. doi:10.1038/nrurol.2017.201 13.Chang KH, Li R, Kuri B, et al. A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer. Cell. 2013;154(5):1074-1084. doi:10.1016/j.-
cell.2013.07.029 14.Hearn JWD, AbuAli G, Reichard CA, et al. HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol. 2016;17(10):1435-1444. doi:10.1016/S1470-2045(16)30227-3 15.Chandrasekar T, Yang JC, Gao AC,
et al. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015;4(3):365-380. doi:10.3978/j.issn.2223-4683.2015.05.02 16.Hearn JWD, Sweeney CJ, Almassi N, et al. HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive
Prostate Cancer. JAMA Oncol. 2020;6(4):e196496. doi:10.1001/jamaoncol.2019.6496